MedTrace Logo

Trial With Metformin in Women With Polycystic Ovary Syndrome

NCT02280057 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2017-02-23

No results posted yet for this study

Summary

The investigators wanted to elucidate the effects of metformin in Polycystic Ovary Syndrome (PCOS) by performing a randomized, double-blinded, placebo-controlled cross-over study.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Metformin

Metformin 1500 mg (=2 pills) per day in six months

DRUG

Placebo

2 pills per day in six months; pills look like metformin pills

Sponsors & Collaborators

  • GEA A/S Denmark

    collaborator UNKNOWN

  • Herning Hospital

    lead OTHER

Principal Investigators

  • Finn F Lauszus, MD, PhD · Gyn Dept. Herning Hospital, Herning, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-09-30
Primary Completion
2002-12-31
Completion
2002-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02280057 on ClinicalTrials.gov